Scholarlink

Background <p>Despite widespread receptivity to risk-based quality management (RBQM) principles, adoption has been limited as drug development stakeholders have lacked quantitative evidence demonstrating return on investment (ROI).</p> Methods <p>Two assessments were conducted to estimate the ROI of RBQM. (1) Clinical trial level ROI was derived by analyzing monitoring cost efficiencies and clinical phase duration reductions under a 10% source data verification (SDV) scenario. (2) Program-level ROI was derived using an expected net present value (eNPV) modeling approach. Both analyses included data based on actual RBQM use in 18 recently completed oncology trials, as well as published and proprietary industry benchmarks.</p> Results <p>RBQM use was associated with reductions of 8–19% in clinical phase durations and monitoring cost reductions of up to 18% under a 10% SDV scenario. Total clinical trial ROIs ranged from $3.2&#xa0;million (phase 1) to $18.9&#xa0;million (phase 3), corresponding to ROI multiples of 6× to 23×. Program-level eNPV gains ranged from $3.8&#xa0;million in phase 1 to $13.8&#xa0;million in phase 3 corresponding to ROI multiples of 4× to 14×.</p> Conclusions <p>The ROI demonstrated at the individual clinical trial level and at the development program level provides a compelling business case for adopting RBQM particularly given alignment with ICH E6 R3 guidelines encouraging risk-based approaches supporting clinical trial planning and execution. Study findings indicate that RBQM-supported oversight not only improves data quality and risk detection but also represents a strategic investment that can help optimize resource allocation, increase development efficiency and speed, and enhance portfolio productivity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Abigail Dirks,
  • Sylviane de Viron,
  • Kenneth McFarlane,
  • Kenneth A. Getz

摘要

Background

Despite widespread receptivity to risk-based quality management (RBQM) principles, adoption has been limited as drug development stakeholders have lacked quantitative evidence demonstrating return on investment (ROI).

Methods

Two assessments were conducted to estimate the ROI of RBQM. (1) Clinical trial level ROI was derived by analyzing monitoring cost efficiencies and clinical phase duration reductions under a 10% source data verification (SDV) scenario. (2) Program-level ROI was derived using an expected net present value (eNPV) modeling approach. Both analyses included data based on actual RBQM use in 18 recently completed oncology trials, as well as published and proprietary industry benchmarks.

Results

RBQM use was associated with reductions of 8–19% in clinical phase durations and monitoring cost reductions of up to 18% under a 10% SDV scenario. Total clinical trial ROIs ranged from $3.2 million (phase 1) to $18.9 million (phase 3), corresponding to ROI multiples of 6× to 23×. Program-level eNPV gains ranged from $3.8 million in phase 1 to $13.8 million in phase 3 corresponding to ROI multiples of 4× to 14×.

Conclusions

The ROI demonstrated at the individual clinical trial level and at the development program level provides a compelling business case for adopting RBQM particularly given alignment with ICH E6 R3 guidelines encouraging risk-based approaches supporting clinical trial planning and execution. Study findings indicate that RBQM-supported oversight not only improves data quality and risk detection but also represents a strategic investment that can help optimize resource allocation, increase development efficiency and speed, and enhance portfolio productivity.